Actelion Pharmaceuticals Ltd

act-050088 - bosentan

 

Study ID Status Type Title
AC-052-113 Completed Protocol Summary Investigation of the pharmacokinetic interaction between bosentan and rifampicin in healthy male subjects
AC-052-115 Completed Protocol Summary Single-center, open-label, three-period, three-treatment, randomized, crossover study investigating the mutual pharmacokinetic interactions between bosentan and a fixed combination of lopinavir/ritonavir (Kaletra®) in healthy male subjects
AC-052-116 Completed Protocol Summary Single-center, open-label, two-period, two-treatment, randomized, crossover study in healthy male subjects to compare the pharmacokinetics of the adult and pediatric formulations of bosentan
AC-052-117 Completed Protocol Summary A single-center, open-label, randomized, two-period, two-treatment, crossover study in healthy subjects to demonstrate bioequivalence of the 125 mg dispersible tablet and the film-coated 125 mg tablet of bosentan
AC-052-281 Completed Protocol Summary A multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the effect of bosentan in patients with stage IV metastatic melanoma treated with dacarbazine
AC-052-320 Completed Protocol Summary A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients with Idiopathic Pulmonary Fibrosis, Open Label Extension
AC-052-321 Completed Protocol Summary Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study
AC-052-322 Completed Protocol Summary Open-Label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3
AC-052-330 Completed Protocol Summary A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of bosentan in patients with interstitial lung disease associated with systemic sclerosis
AC-052-331 Completed Protocol Summary A randomized, double-blind, placebo-controlled, multi-center study to assess the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with systemic sclerosis
1 2 3 4 5